Astrana Health 3Q 2026: Revenue $1.02B, EPS $0.26 — 10-Q Summary

Astrana Health reported 3Q 2026 revenue of $1.02B, up 7% YoY, and net income of $13.0M, compared to $373K last year. Growth was driven by 9% increase in capitation revenue. Care Partners saw 8% revenue growth and 94% operating income rise, while Care Delivery revenue increased 5% but operating loss widened. Care Enablement revenue rose 5% with 4% higher operating income. Astrana managed 29 IPAs and 1.5M patients as of September 30, 2026.

Original reporting
Published Nov 6, 2026, 11:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 11:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Astrana Health 3Q 2026: Revenue $1.02B, EPS $0.26 — 10-Q Summary — source image
Decision brief

The 30-second read

$ASTHBullishMed
01

Why it matters

The earnings beat may trigger short‑term buying and could set a higher baseline for future guidance.

02

Market read

First‑report earnings data for Astrana Health provides actionable insight for traders focusing on health‑services equities.

03

What to watch

Rising operating costs in Care Delivery could pressure margins if patient‑visit growth slows.

Relevance 7/10Novelty 7/10Timing: post‑release today

Background

Astrana Health is a U.S. managed‑care company that recently transitioned many enrollees to full‑risk contracts (RKKs).

Company-level read

Ticker impact

$ASTHBullishHigh confidence
Context

Astrana Health reported Q3 2026 revenue of $1.02B and EPS $0.26, a fresh earnings disclosure.

Expected impact

likely upside as investors price in the earnings beat and higher profitability

Evidence & confidence

Revenue rose 7% YoY and net income jumped from $0.373M to $13.0M, indicating improved margins and operational execution.

Market effects

Highlights strength in the managed‑care and capitation revenue segment, potentially benefiting peers in health‑services.

U.S. health‑services sector may see modest buying pressure.

Limited to U.S. health‑services investors; no broader macro effect.

Counterpoint

If guidance falls short of market expectations despite the earnings beat, the stock could face disappointment.

Key entities

  • Astrana Health, Inc.

    Issuer of the Q3 2026 earnings report.

Related articles

$ASTHHighAI 8/10

Astrana Health Earnings Call Highlights Growth and Deleveraging

Astrana Health (ASTH) reported Q3 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). The company highlighted organic growth, debt reduction, and favorable Medicare trends. Management maintained full-year guidance, expecting revenue of $3.9B-$4B and adjusted EBITDA of $261M-$274M. Challenges include Medicaid pressure and seasonality.

$ASTHMed

Astrana Health Inc (ASTH) (Q3 2026) Earnings Call Highlights: Record Revenue and EBITDA

Astrana Health Inc (ASTH) reported Q3 2026 earnings, highlighting record revenue and EBITDA growth. CEO Brandon Sim discussed Medicaid membership attrition, Medicare Advantage dynamics, and care enablement business momentum. The company expects mid-teens EBITDA growth despite Medicaid headwinds. A cybersecurity incident is under investigation, and a new 'premiums at risk' disclosure was introduced for ACO business transparency.

$ASTHHighAI 8/10

Astrana Health (ASTH) Q3 2026 Earnings Call Transcript

Astrana Health (ASTH) reported Q3 2026 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). Membership grew to 1.5M, with Medicare Advantage increasing organically. The company completed acquisitions and partnerships, expanding its presence. Medical cost trends were slightly better than expected, with Texas operations performing ahead of plan. Free cash flow reached $105M, and net leverage was reduced to 2.2x.

$ASTHMed

Astrana Health Q3 Earnings Call Highlights

Astrana Health reported 1.5 million members under management, with Medicare Advantage growth offsetting Medicaid attrition. The company expects Medicaid membership to decline 10-15% in 2027, impacting adjusted EBITDA. Medical cost trends were slightly better than expected, with Medicare Advantage margins stable. Astrana plans 82% of capitation revenue from full-risk arrangements by 2026 and completed acquisitions and partnerships.